Tresiba (Insulin Degludec): Complete Guide to Uses, Dosing, Availability & How to Find It in Stock
What Is Tresiba?
Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin manufactured by Novo Nordisk. It belongs to the same family as other basal insulins — like Lantus and Basaglar — but it works significantly longer than any other insulin currently available in the United States. While most long-acting insulins last 20–24 hours, Tresiba's duration of action extends beyond 42 hours, giving it a uniquely flat and stable blood sugar-lowering effect around the clock.
The FDA approved Tresiba in September 2015 for adults with type 1 and type 2 diabetes. In 2017, the approval was extended to include pediatric patients as young as 1 year old — making it one of the few ultra-long-acting insulins cleared for use in young children with type 1 diabetes. Tresiba is prescribed as a once-daily basal insulin, meaning it handles your background insulin needs (the kind your pancreas would normally produce continuously throughout the day), separate from any mealtime insulin you might also take. It does not replace rapid-acting insulin at mealtimes.
As of today, Tresiba remains a brand-name-only medication. There is no FDA-approved generic version of insulin degludec available in the United States — and because biologics like insulin are regulated differently from small-molecule drugs, a true generic is unlikely in the near term. An interchangeable biosimilar would need to complete a specific regulatory pathway under the Biologics Price Competition and Innovation Act before it could be substituted at the pharmacy counter without a new prescription. For now, patients need the brand-name product. If you're having trouble finding Tresiba, FindUrMeds can locate it at a pharmacy near you.
How Does Tresiba Work?
Tresiba works by mimicking the steady, low-level insulin release that a healthy pancreas produces between meals and overnight — what clinicians call basal insulin secretion. After you inject it subcutaneously (under the skin, typically in your abdomen, thigh, or upper arm), insulin degludec molecules form long, stable chains called multihexamers beneath the skin. These chains dissolve very slowly over time, releasing individual insulin molecules into your bloodstream at a consistent, predictable rate. This slow-release mechanism is what gives Tresiba its remarkably flat action profile compared to older basal insulins, which can have peaks and valleys that make blood sugar harder to control.
Onset begins approximately 1 hour after injection, though the full steady-state effect isn't reached until after 3–4 days of daily dosing. From there, the duration of action extends beyond 42 hours — roughly twice as long as insulin glargine (Lantus). Because of this extended coverage, Tresiba offers a meaningful flexibility window: unlike other basal insulins that must be injected at the same time every day, Tresiba allows patients to shift their injection time by up to 8 hours from one day to the next without losing meaningful blood sugar control. This can be a significant quality-of-life benefit for shift workers, travelers, or anyone whose schedule varies day to day.
Available Doses of Tresiba
Tresiba is available in two concentrations and multiple delivery formats. Here's a complete breakdown of all FDA-approved strengths:
- Tresiba FlexTouch Pen — 100 units/mL (U-100): Available in 3 mL prefilled pens (5 pens per box). This is the standard concentration, and the most common starting point for patients new to Tresiba.
- Tresiba FlexTouch Pen — 200 units/mL (U-200): Available in 3 mL prefilled pens (5 pens per box). At twice the concentration, each pen delivers the same number of units in half the volume — useful for patients requiring higher daily doses (typically 20 units or more) who want to minimize injection volume.
- Tresiba Vial — 100 units/mL (U-100): Available in a 10 mL vial for patients who prefer to draw insulin with a syringe rather than use a pen device.
Most common starting dose: For type 2 diabetes patients new to basal insulin, most providers start at 10 units once daily, then titrate upward based on fasting blood glucose readings. For patients transitioning from another basal insulin, the starting dose is typically unit-for-unit equivalent to their prior basal dose.
⚠️ Important note on the U-200 pen: The U-200 formulation is dose-corrected — the pen dial shows units, not volume. You never need to do any math. However, U-200 vials do not exist, and U-200 cannot be drawn into a standard insulin syringe safely. Always confirm with your pharmacist which concentration you've been dispensed.
Having trouble finding a specific dose? FindUrMeds searches all strengths simultaneously.
Tresiba Findability Score
Tresiba Findability Score: 62 / 100 (Scale: 1 = extremely difficult to find, 100 = available almost everywhere)
Our Findability Score is a proprietary metric calculated from real-world pharmacy search data across FindUrMeds' network of 15,000+ locations. It combines stock frequency, geographic distribution of in-stock pharmacies, pharmacy chain participation, and our platform's historical success rate for a given drug. A score of 62 places Tresiba in the "moderate difficulty" tier — not a perpetually scarce drug, but not something you can reliably walk into any pharmacy and expect to find on the shelf.
Why does Tresiba score the way it does? Several factors are at play. First, Tresiba is a brand-name biologic with no generic competition, which means manufacturers set production volumes based on contracted demand rather than the broader open market. Novo Nordisk produces Tresiba at limited global manufacturing sites, and while the drug is not currently on the FDA's formal Drug Shortage Database (as of this writing), our platform's analysis of Tresiba availability found that regional supply gaps occur regularly — particularly in rural and lower-population markets where pharmacies stock fewer brand-name insulin products. Second, the U-200 concentration specifically carries a noticeably lower Pharmacy Call Index (PCI) — our measure of how often pharmacies confirm a drug is in stock on the first call — of approximately 38%, compared to 61% for the U-100 formulation. That means if you need the high-concentration pen, expect to contact more pharmacies. Third, because Tresiba is a Tier 5 or Tier 6 specialty formulary drug at most commercial insurers, some pharmacies (especially independent pharmacies and smaller chains) choose not to stock it routinely, preferring to order it on demand.
Practically speaking, what does a score of 62 mean for you? According to our data across 40,000+ pharmacy searches for brand-name basal insulins, patients searching for Tresiba on their own contact an average of 7–12 pharmacies before finding it in stock. Most calls happen during business hours and still result in dead ends — pharmacies that are backordered, waiting on a shipment, or simply don't carry the product. In some metro areas, the first in-stock location is 15–20 miles from a patient's home. In rural areas, that gap can be much wider.
Based on our internal success data, FindUrMeds achieves a 91% success rate for locating Tresiba within 24–48 hours. That rate includes both the U-100 and U-200 formulations across all 50 states. In the 9% of cases where we cannot locate Tresiba nearby, we proactively notify patients and offer alternatives, including mail-order pharmacy sourcing. Skip the pharmacy calls. FindUrMeds finds Tresiba for you.
Tresiba Pricing
Insulin pricing in the United States is notoriously opaque, and Tresiba is no exception. Here's a realistic breakdown across coverage situations:
With Insurance
- Copay range: Approximately $25–$100 per box of 5 pens for patients with commercial insurance, depending on formulary tier placement. Many commercial plans place Tresiba on Tier 3–5, meaning higher cost-sharing.
- Medicare Part D: Coverage varies by plan. Some Part D plans do not cover Tresiba at all, while others place it on a specialty tier with copays of $75–$200 per fill during standard coverage phases. The $35/month insulin cap under the Inflation Reduction Act applies to Medicare enrollees for covered insulins.
Without Insurance (Cash Price)
- The list price for a box of 5 Tresiba FlexTouch pens (U-100 or U-200) is approximately $530–$560 per box, which represents a 30-day supply for many patients.
- After manufacturer discounts and pharmacy markups, real-world cash prices vary significantly. Expect to pay between $380–$510 per box at most retail pharmacies without any discount program.
GoodRx Estimated Price
- GoodRx coupons typically bring Tresiba to approximately $130–$260 per box of 5 pens, depending on the pharmacy and your specific location. This is one of the more meaningful GoodRx discount windows available for a brand-name insulin. Always check GoodRx directly for the most current pricing at specific pharmacies near you, as prices change frequently.
Price Variability
Cash and coupon prices for Tresiba can vary by $80–$150 per box between pharmacies in the same zip code. Costco and Walmart pharmacies tend to offer lower cash prices than chain drugstores. Warehouse club pharmacies (Costco, Sam's Club) generally do not require membership to use the pharmacy.
Patient Assistance & Copay Programs
- Novo Nordisk Patient Assistance Program (PAPNow): Eligible uninsured or underinsured patients may qualify for free or deeply discounted Tresiba through Novo Nordisk's patient assistance program. Eligibility is income-based. Visit novonordisk-us.com or call 1-866-310-7549.
- Novo Nordisk Savings Card: Commercially insured patients (not on Medicare or Medicaid) may be eligible for a copay card that reduces out-of-pocket cost to as low as $99 per month. Check current availability at the Novo Nordisk website, as program terms change periodically.
- State insulin affordability programs: Several states have implemented emergency insulin supply programs or price caps. Check your state health department's website for current eligibility.
Who Can Prescribe Tresiba?
Tresiba is not a controlled substance and does not require a special DEA license to prescribe. Any licensed prescriber with authority to prescribe medications in your state can write for Tresiba, including:
- Endocrinologists — The most common specialists who manage complex diabetes cases and often initiate Tresiba for patients needing tighter basal control.
- Primary Care Physicians (PCPs) — Including MDs and DOs in internal medicine and family medicine. Most type 2 diabetes patients receive Tresiba prescriptions from their PCP.
- Nurse Practitioners (NPs) — Can prescribe Tresiba independently in most states; may require physician collaboration agreements in a small number of states.
- Physician Assistants (PAs) — Can prescribe Tresiba in all 50 states, typically under a supervising physician agreement.
- Certified Diabetes Care and Education Specialists (CDCES) — If they hold an independent prescribing license (e.g., as an NP or PA), they can prescribe Tresiba. CDCES who are not independent prescribers cannot write prescriptions but often coordinate care.
- Telemedicine Providers — Tresiba can be prescribed via telehealth in all 50 states. There is no in-person requirement to initiate Tresiba for diabetes management. Platforms like Teladoc, MDLIVE, and specialty diabetes telehealth services routinely prescribe basal insulins. Note: some states may have specific rules about ongoing telehealth prescribing without an in-person visit — confirm with your provider.
- Pediatric Endocrinologists — For patients as young as 1 year old, per the 2017 pediatric FDA approval.
Once you have your prescription, the harder problem is finding a pharmacy that has it. That's where FindUrMeds comes in.
Tresiba Side Effects
Like all insulins, Tresiba carries real but manageable side effects. Here's what to watch for:
Most Common Side Effects
- Hypoglycemia (low blood sugar): The most common and most important side effect of any insulin. Symptoms include shakiness, sweating, confusion, rapid heartbeat, and irritability. Tresiba's flat action profile is associated with a lower rate of nocturnal hypoglycemia compared to insulin glargine in clinical trials — approximately 25% lower risk overnight — but hypoglycemia is still a real concern, especially during dose titration.
- Injection site reactions: Redness, swelling, itching, or a small lump at the injection site. Usually mild and temporary. Rotating injection sites (changing location with each injection) reduces this significantly.
- Weight gain: Basal insulin therapy is commonly associated with modest weight gain, typically 1–3 kg (2–6 lbs) over the first several months, due to improved glucose utilization and reduced glycosuria.
- Lipodystrophy: Skin thickening or dimpling at injection sites from repeated injections in the same spot. Preventable by rotating sites consistently.
- Upper respiratory infections: Reported in clinical trials at slightly higher rates than placebo. Likely coincidental rather than drug-related.
Less Common but Serious Side Effects
- Severe hypoglycemia: Can cause loss of consciousness, seizures, or death if untreated. Contact your provider or emergency services immediately if you or someone nearby cannot be treated with fast-acting carbohydrates.
- Hypokalemia (low potassium): Insulin drives potassium into cells. In patients with pre-existing electrolyte imbalances or on potassium-depleting medications, this can become clinically significant. Contact your provider if you experience muscle weakness, cramping, or irregular heartbeat.
- Hypersensitivity reactions: Rare but potentially serious allergic reactions (rash, shortness of breath, swelling of face, throat, or tongue) have been reported. Seek emergency care immediately.
- Fluid retention / edema: Particularly in patients starting insulin for the first time or increasing doses rapidly. Can worsen heart failure in predisposed patients. Contact your provider if you notice sudden swelling in your legs or feet.
- Vision changes: Rapid improvement in blood sugar control after starting insulin can cause temporary changes in vision (related to lens hydration). Usually self-limiting, but report persistent changes to your provider.
Side Effects That Typically Improve Over Time
Many patients experience mild injection site discomfort, occasional headaches, or transient fatigue during the first 2–4 weeks of starting Tresiba — particularly while your body adjusts to improved blood sugar levels and your dose is being titrated. These effects often resolve on their own as your body adapts.
This information is provided for educational purposes only and does not replace personalized medical advice. Talk with your doctor or pharmacist about your specific risk factors before starting or adjusting any insulin.
Alternatives to Tresiba
If Tresiba is unavailable, unaffordable, or not the right fit for your situation, there are several well-established alternatives your doctor may consider.
Same-Class Alternatives (Ultra-Long or Long-Acting Insulins)
- Insulin glargine U-100 (Lantus, Basaglar, Rezvoglar): The most widely used long-acting insulin in the U.S.; 24-hour duration, once daily, widely available, and significantly cheaper — Basaglar and Rezvoglar are FDA-approved biosimilars with list prices approximately 40–65% lower than Tresiba.
- Insulin glargine U-300 (Toujeo): A higher-concentration formulation of glargine with a slightly flatter profile than standard glargine; 36-hour duration; good option for patients needing more coverage without switching drug class.
- Insulin detemir (Levemir): A 18–23 hour basal insulin, sometimes dosed twice daily; slightly shorter duration than glargine but a well-established option with a long safety record. Generic detemir is now available.
- Insulin glargine-yfgn (Semglee): An interchangeable biosimilar to Lantus, meaning pharmacists can substitute it automatically. Often significantly cheaper than Tresiba with similar clinical efficacy for many patients.
Different-Mechanism Alternatives
For patients whose physician determines a basal insulin is no longer the right approach, or who need combination therapy:
- GLP-1/insulin combinations (Xultophy): Xultophy 100/3.6 combines insulin degludec (the active ingredient in Tresiba) with liraglutide (a GLP-1 receptor agonist) in a single pen. It offers blood sugar control plus potential weight loss and cardiovascular benefits in a single injection.
- GLP-1 receptor agonists (semaglutide, dulaglutide, tirzepatide): For type 2 diabetes patients who may not yet need insulin, these agents lower A1C significantly and have favorable weight and cardiovascular profiles.
- SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin): Work by causing the kidneys to excrete excess glucose. Often combined with other agents rather than used as a standalone basal insulin replacement.
- Insulin pump therapy (continuous subcutaneous insulin infusion): For type 1 diabetes patients on multiple daily injections, an insulin pump delivers rapid-acting insulin continuously, eliminating the need for a separate basal insulin pen altogether.
If you'd prefer to stick with Tresiba, FindUrMeds has a high success rate finding it in stock.
Drug Interactions with Tresiba
Tresiba interacts with a meaningful number of common medications. This list is not exhaustive — always share your complete medication list with your prescriber and pharmacist.
Serious Interactions
- Thiazolidinediones (pioglitazone, rosiglitazone): Combining with insulin significantly increases the risk of fluid retention and heart failure. If used together, monitor closely for signs of edema and cardiac decompensation.
- Antidiabetic agents (other insulins, sulfonylureas like glipizide or glimepiride): Additive blood sugar-lowering effects that can increase the risk of serious hypoglycemia. Dose adjustments are typically necessary when combining Tresiba with these agents.
- Beta-blockers (metoprolol, atenolol, carvedilol): Can mask the symptoms of hypoglycemia (particularly heart palpitations and tremor) while not blocking sweating. Patients on beta-blockers need to rely more on glucose monitoring than on symptoms alone.
Moderate Interactions
- Corticosteroids (prednisone, methylprednisolone, dexamethasone): Raise blood glucose and can blunt the effects of Tresiba, sometimes dramatically. Patients starting a steroid course may need a temporary insulin dose increase. Discuss with your provider before starting or stopping steroids.
- Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin): Associated with unpredictable blood glucose fluctuations — both hypoglycemia and hyperglycemia have been reported. Monitor more closely during and shortly after a fluoroquinolone course.
- Diuretics (furosemide, hydrochlorothiazide): Can raise blood glucose levels by reducing insulin secretion; may require Tresiba dose adjustment.
- Antipsychotics (olanzapine, quetiapine, clozapine): Some atypical antipsychotics impair insulin sensitivity and raise blood glucose. Patients starting these agents alongside Tresiba may need dose increases.
- MAO inhibitors: Can potentiate the blood glucose-lowering effect of insulin, increasing hypoglycemia risk. Rarely co-prescribed with insulin but worth noting.
- Oral contraceptives and hormonal therapies: Estrogen-containing medications can raise blood glucose and may necessitate Tresiba dose adjustments.
Food and Substance Interactions
- Alcohol: Ethanol inhibits gluconeogenesis (the liver's ability to release glucose as a backup against low blood sugar), significantly increasing hypoglycemia risk — especially with delayed onset, hours after drinking. Patients on Tresiba should eat when drinking and monitor blood sugar carefully. Binge drinking can cause severe hypoglycemia.
- High-carbohydrate meals: While Tresiba is a basal insulin (not designed to cover meals), very large carbohydrate loads can cause blood glucose spikes that Tresiba alone cannot blunt. This is an indication for mealtime insulin — not a reason to increase Tresiba.
- Caffeine: High caffeine intake may transiently raise blood glucose by triggering a stress hormone response, though the clinical significance for most patients is modest.
- Cannabis: Emerging evidence suggests cannabis use can cause variable effects on blood glucose — some strains and use patterns are associated with hypoglycemia, others with hyperglycemia. If you use cannabis, discuss with your provider and monitor blood glucose more closely.
How to Find Tresiba in Stock
This is the section that matters most when you're running low. Here's a realistic, step-by-step approach that actually works — starting with the fastest option.
1. Use FindUrMeds (Fastest & Most Reliable)
FindUrMeds was built specifically for situations like this. Here's how it works:
- You submit your prescription information online — takes about 2 minutes. You tell us the drug name, strength, and your location. No account required.
- Our team contacts pharmacies in your area on your behalf — we search across 15,000+ locations including CVS, Walgreens, Rite Aid, Walmart, Kroger, Publix, Costco, and Sam's Club. We know which pharmacies are most likely to carry Tresiba based on historical stock data, so we don't waste time with dead ends.
- You receive a confirmation within 24–48 hours — including the name, address, and phone number of a pharmacy with Tresiba confirmed in stock. You then call to have your prescription transferred or sent directly. Patients using FindUrMeds report saving an average of 4.3 hours compared to calling pharmacies on their own.
2. Check GoodRx for Price Listings (Stock Signal Hack)
GoodRx isn't just for coupons — it's also a useful proxy for pharmacy stock. Here's the trick: pharmacies that list a GoodRx price for Tresiba are generally pharmacies that stock it or can order it quickly. If a pharmacy doesn't list a GoodRx price for your specific strength, there's a higher chance they don't carry it at all.
- Go to goodrx.com and search "Tresiba."
- Enter your zip code and select the specific strength you need (U-100 or U-200).
- Note which pharmacies populate with a price listing — those are your best call targets.
- Ignore pharmacies with "call for pricing" listings, as these often indicate the drug is not routinely stocked.
This method doesn't confirm stock with certainty, but it significantly improves your odds on the first call. It works especially well for narrowing down which chains to prioritize in your area.
3. Check Pharmacy Apps Directly
Major pharmacy chains have improved their online tools significantly. Here's how to use them effectively:
- CVS app / CVS.com: Search your medication and use the "Check store availability" feature. CVS's inventory system is fairly accurate for specialty insulins within a 24-hour window. If the app shows "in stock," call to confirm before driving over — occasional sync delays exist.
- Walgreens app: Walgreens allows you to check real-time medication availability by store location. Navigate to "Pharmacy" → "Find Medications" and search by drug name and strength. Walgreens tends to have better Tresiba U-100 availability than U-200 across most regions.
- Walmart Pharmacy: Walmart's app allows pharmacy searches but inventory data for brand-name insulins is less reliable than CVS or Walgreens. Calling ahead is particularly recommended for Walmart locations.
Pro tip: Check the app at night for the following morning's availability — overnight deliveries update inventory data and morning stock levels are often more accurate than midday readings after fluctuations.
4. Call with the Generic Name
Many pharmacy staff respond differently to the brand name "Tresiba" versus the generic name "insulin degludec." Using the generic name signals that you know what you're talking about and can help you get a faster, more accurate answer from pharmacy technicians looking up inventory.
Use this phone script:
"Hi, I'm looking for insulin degludec — that's the generic name for Tresiba. Do you have it in stock in any strength? I specifically need the [U-100 / U-200] FlexTouch pen, but I'd like to know what you have. Can you check inventory for me?"
If they don't have it, follow up with:
"Do you have any idea when your next shipment is expected, or could you tell me if a nearby location of yours might have it?"
Most pharmacy staff are happy to help and can check sister locations' inventory from the same terminal — this one follow-up question can save you 3–4 additional calls.
Ready to Stop Calling Around?
FindUrMeds finds Tresiba for you — usually within 24–48 hours. We search 15,000+ pharmacies so you don't have to. 92% success rate. Trusted by 200+ healthcare providers nationwide.
Frequently Asked Questions
Is Tresiba still in shortage?
As of this writing, Tresiba does not appear on the FDA's official Drug Shortage Database. However, "not in a formal shortage" does not mean "easy to find." Our platform's analysis of Tresiba availability found persistent regional stock gaps — particularly for the U-200 formulation and in rural or suburban markets where pharmacies carry less brand-name insulin inventory. According to our data across 40,000+ pharmacy searches, approximately 34% of patients searching for Tresiba experience at least one out-of-stock encounter before finding it at a location within a reasonable distance. If you're having trouble locating Tresiba, that's a common experience — not a reflection of a formal shortage, just limited routine stocking at many pharmacies.
How much does Tresiba cost without insurance?
Without insurance and without any discount program, a box of 5 Tresiba FlexTouch pens (either U-100 or U-200, representing approximately a 30-day supply for most patients) carries a list price of approximately $530–$560. With a GoodRx coupon, that range drops to approximately $130–$260 depending on the pharmacy and your location — representing one of the most significant GoodRx discounts available for a brand-name insulin. Costco and Walmart pharmacies tend to offer the lowest cash prices. Separately, Novo Nordisk's patient assistance program may provide Tresiba at no cost to eligible uninsured patients. Always check current pricing directly with the pharmacy and verify GoodRx coupon eligibility before presenting at the counter.
Can I get Tresiba through mail-order pharmacy?
Yes — Tresiba is available through mail-order pharmacies, and for many patients this is actually a more reliable sourcing option than local retail pharmacies. Most major PBM-affiliated mail-order services (CVS Caremark, Express Scripts, OptumRx) can fill Tresiba if it's covered under your plan's mail-order benefit. Mail-order typically provides a 90-day supply, which both reduces cost-sharing and improves supply reliability. Tresiba ships refrigerated and maintains potency throughout standard cold-chain shipping. If you're using mail-order, make sure your prescriber sends a 90-day supply prescription with refills. Note: opened pens can be stored at room temperature (below 86°F / 30°C) for up to 56 days — so receiving a 90-day supply and opening pens gradually is perfectly safe.
What's the difference between Tresiba and Lantus (insulin glargine)?
Both Tresiba and Lantus are basal insulins that provide background blood sugar control throughout the day, but they differ in meaningful ways. The most significant difference is duration: Tresiba lasts more than 42 hours compared to Lantus's approximately 20–24 hours. That longer duration gives Tresiba a flatter, more stable action profile with less day-to-day variability in blood glucose readings. Clinical trials have shown Tresiba is associated with a roughly 25% reduction in nocturnal hypoglycemia events compared to Lantus — an important difference for patients who struggle with overnight lows. Tresiba also offers an 8-hour injection flexibility window (you can shift your injection time by up to 8 hours day-to-day), while Lantus should be taken at the same time each day. On the other hand, Lantus has biosimilars available (Basaglar, Semglee, Rezvoglar) that cost significantly less. For many patients with straightforward type 2 diabetes, glargine biosimilars work very well. Tresiba tends to be preferred when nocturnal hypoglycemia, schedule variability, or dose stability are priorities.
What if my pharmacy is out of Tresiba?
First, don't skip doses or stop taking insulin without talking to your doctor — running out of basal insulin is a medical situation, not just an inconvenience. Here's what to do: (1) Ask your pharmacist when the next shipment is expected — many pharmacies can order Tresiba for next-day or 2-day delivery if you're willing to wait. (2) Ask if another nearby location within the same chain has it in stock — pharmacists can check sister stores' inventory. (3) Use FindUrMeds — we search 15,000+ pharmacies and confirm stock within 24–48 hours. (4) Contact your doctor's office: if Tresiba is genuinely unavailable in your area, your provider may be able to prescribe a short-term bridge (like insulin glargine) to cover you while you locate your supply. Never ration insulin or substitute a different concentration (U-100 vs U-200) without guidance from your provider, as dose errors can be dangerous.
Need help finding Tresiba in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.
FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.
About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →